Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Background:

• Although survival of glioblastoma (GBM) has improved using standard of care chemoradiation, outcomes are still poor. Most patients will recur within months to years, in or adjacent to their previous treatment field.
• There is no consensus standard of care for patients with recurrent GBM. Re-resection is recommended, if possible, to improve symptoms and decrease tumor volume. However, this treatment option is possible only in a minority of patients, and for these patients re-irradiation has emerged as a possible treatment.
• Modern radiation therapy (RT) techniques allow delivery of re-irradiation while minimizing the dose to previously treated organs at risk (OAR) within the radiation field.
• Data from a recently completed clinical trial at our center (16-C-0081, NCT02709226) suggests that the Maximum Tolerated Dose (MTD) of re-irradiation in 350 cGy fractions is 4200 cGy.

Objective:

-To determine the maximum tolerated dosage of daily re-irradiation in participants with recurrent Grade 4 gliomas

Eligibility:

• A histologic diagnosis of GBM, gliosarcoma, or transformation, from a lower grade to a grade 4 brain tumor.
• Previous glioma irradiation to curative-intent doses.
• Age >= 18.
• Karnofsky performance scale (KPS) >= 70.

Design:

• This is a single center phase I trial using a '3 + 3' design and a three (3) dose level hypofractionation schema to enroll a maximum of 21 evaluable participants.
• Prior to radiation therapy, participants will undergo laboratory evaluations, magnetic resonance imaging (MRI), and a treatment planning computed tomography (CT).
• RT will be administered daily 4 days a week for 1, 2, or 3 weeks in the Radiation Oncology Branch, NCI, at NIH. Radiation will be delivered on consecutive days, 4 fractions per week via a linear accelerator using 6 megavoltage (MV) photons or greater.
• Follow-up visits following RT are planned at 1 month, every 2 months for years 1-2, and every 3 months for year 3. These visits will be stopped earlier in case of progression. After progression or 3 years of follow-up, participants will be followed remotely for survival

until 5 years after treatment completion.

• INCLUSION CRITERIA:
• Histologic diagnosis of primary glioblastoma or gliosarcoma of the brain, or secondary glioblastoma of the brain due to transformation from a lower grade to a grade 4 tumor.
• Age >= 18.
• KPS >= 70%.
• Previous tumor irradiation to curative-intent doses.
• Radiation dose constraints must be achievable based on assessment with MRI and treatment planning CT.
• Participants must have adequate organ and marrow function as defined below:

• Absolute neutrophil count (ANC) >= 1,000/microL
• Platelets >= 100,000/microL
• Individuals of child-bearing potential (IOCBP) and individuals who can father children must agree to use effective contraception (barrier, hormonal, intrauterine device, surgical sterilization, abstinence) from study entry and through 6 months after the last study treatment (restricted period). Individuals who can father children must not freeze or donate sperm within the same period.
• Nursing participants must be willing to discontinue nursing from study treatment initiation through 6 months after the last study treatment.
• The ability of a participant to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• Recent systemic therapy prior to the initiation of the study therapy as follows:

• Bevacizumab used for reasons other than tumor progression or symptomatic management within 2 weeks.
• Temozolomide within 2 weeks.
• Cytotoxic chemotherapy within 3 weeks.
• Any investigational agents within 2 weeks.
• Participants who are unable to undergo MRI evaluation or receive gadolinium contrast for any reason.
• Any prior therapy after surgical re-resection or biopsy within 2 weeks prior to the initiation of the study therapy.
• Requiring radiation therapy within 12 months prior to the initiation of study therapy.
• History of prior therapy with Novacure TTF, Gliadel wafers, or GammaTile therapy.
• Positive beta-human chorionic gonadotropin (HCG) pregnancy test performed in individuals of childbearing potential at screening.
• Participants with known or suspected radiation sensitivity syndromes.
• Uncontrolled intercurrent illness evaluated by medical history and physical exam that are not stable and would potentially increase the risk to the participant.